Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adverse drug reactions

This article was originally published in The Tan Sheet

Executive Summary

NDMA finds it "difficult to detect from the published report" in the April 15 Journal of the American Medical Association of the incidence of ADRs in hospitalized patients "the scope and the extent of reported OTC usage by the study population." Widespread lay media coverage of the study has cited ADRs both from Rx and OTC drugs, although the JAMA article does not mention OTC drugs. The study, a meta-analysis of 39 prospective studies from U.S. hospitals, was designed to estimate the incidence of serious and fatal ADRs in hospital patients, both those already registered as in-patients and those who were admitted after presenting with suspected drug-related ADRs. The analysis by Jason Lazarou, University of Toronto, et al., excluded errors in drug administration, noncompliance, overdose, drug abuse, therapeutic failures and "possible" ADRs. Lazarou et al. conclude the incidence of ADRs is "extremely high" and represents "an important clinical issue"...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel